Jacobs & Co. CA Lowers Stock Position in Zoetis Inc. $ZTS

Key Points

• Jacobs & Co. CA cut its Zoetis position by 20.4% in the second quarter, selling 19,912 shares and retaining 77,738 shares worth approximately $5.6 million. Institutional investors collectively own 92.8% of the company.
• Zoetis beat second-quarter adjusted earnings expectations with EPS of $1.87, but revenue of $2.47 billion fell short of estimates and was essentially flat year over year amid weaker veterinary traffic and competitive pressure.
• Fiscal 2026 guidance was reduced to adjusted EPS of $6.15–$6.25 and revenue of $9.1–$9.3 billion, contributing to the stock’s decline. Shares recently traded near $72.53, while analysts maintain a consensus “Hold” rating with an average price target of $115.50.

Jacobs & Co. CA reduced its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 20.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 77,738 shares of the company's stock after selling 19,912 shares during the period. Jacobs & Co. CA's holdings in Zoetis were worth $5,586,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. RFG Advisory LLC grew its position in Zoetis by 4.9% in the 4th quarter. RFG Advisory LLC now owns 1,708 shares of the company's stock worth $215,000 after purchasing an additional 80 shares in the last quarter. Quest 10 Wealth Builders Inc. lifted its position in shares of Zoetis by 4.7% during the 4th quarter. Quest 10 Wealth Builders Inc. now owns 1,904 shares of the company's stock worth $240,000 after buying an additional 86 shares in the last quarter. Financial Engines Advisors L.L.C. boosted its stake in shares of Zoetis by 4.4% in the 3rd quarter. Financial Engines Advisors L.L.C. now owns 2,043 shares of the company's stock worth $299,000 after buying an additional 87 shares during the last quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych grew its holdings in shares of Zoetis by 20.9% in the fourth quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych now owns 520 shares of the company's stock valued at $65,000 after acquiring an additional 90 shares in the last quarter. Finally, Physician Wealth Advisors Inc. grew its holdings in shares of Zoetis by 17.4% in the first quarter. Physician Wealth Advisors Inc. now owns 615 shares of the company's stock valued at $73,000 after acquiring an additional 91 shares in the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Zoetis

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Zoetis reported second-quarter adjusted earnings of $1.87 per share, above the $1.84–$1.85 analyst consensus and up from $1.76 a year earlier. The earnings beat provides some support for the stock. Zoetis Surpasses Q2 Earnings Estimates
• Positive Sentiment: JPMorgan lowered its price target from $130 to $115 but maintained an Overweight rating, implying substantial potential upside from recent levels. The target reduction reflects more conservative estimates rather than a bearish long-term view.
• Neutral Sentiment: Zoetis appointed James “Jay” Saccaro as executive vice president and chief financial officer, with the announcement also describing an expanded finance and operating leadership role. The change may improve execution, but its near-term effect on results is unclear. Zoetis Appoints Jay Saccaro
• Negative Sentiment: Second-quarter revenue was $2.47 billion, below the $2.50 billion consensus and essentially flat year over year. Management cited weaker veterinary traffic, customer price sensitivity and competitive pressure in companion-animal products, with promotions being used to defend market share. ZTS Q2 Earnings Call Flags Deeper Companion Animal Pressure
• Negative Sentiment: Zoetis cut fiscal 2026 guidance to adjusted EPS of $6.15–$6.25 from expectations near $6.87, and revenue guidance to $9.1–$9.3 billion versus consensus of roughly $9.8 billion. The outlook reduction is the primary reason the stock has declined despite the quarterly earnings beat. Zoetis Q2 Earnings Beat Estimates, Revenues Miss, 2026 View Cut

Zoetis Stock Performance

Shares of ZTS stock opened at $72.53 on Friday. The stock has a market capitalization of $30.41 billion, a P/E ratio of 11.95, a PEG ratio of 1.26 and a beta of 0.74. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80. The firm's 50 day moving average is $76.66 and its 200 day moving average is $100.75. Zoetis Inc. has a 12 month low of $71.47 and a 12 month high of $160.48.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, beating analysts' consensus estimates of $1.85 by $0.02. Zoetis had a net margin of 27.49% and a return on equity of 70.95%. The business had revenue of $2.47 billion during the quarter, compared to analyst estimates of $2.50 billion. During the same period in the previous year, the business earned $1.76 EPS. Zoetis's revenue was down .2% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, sell-side analysts anticipate that Zoetis Inc. will post 6.43 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be paid a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date is Monday, July 20th. Zoetis's payout ratio is presently 34.93%.

Insider Buying and Selling

In related news, Director Frank A. Damelio purchased 6,650 shares of the firm's stock in a transaction dated Wednesday, May 13th. The shares were purchased at an average cost of $75.39 per share, for a total transaction of $501,343.50. Following the completion of the transaction, the director directly owned 21,458 shares in the company, valued at approximately $1,617,718.62. This represents a 44.91% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Michael B. Mccallister purchased 3,000 shares of the stock in a transaction dated Monday, May 11th. The stock was purchased at an average cost of $77.76 per share, for a total transaction of $233,280.00. Following the completion of the acquisition, the director owned 24,524 shares of the company's stock, valued at approximately $1,906,986.24. This represents a 13.94% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders have purchased 11,650 shares of company stock valued at $886,384. Corporate insiders own 0.22% of the company's stock.

Analysts Set New Price Targets

A number of brokerages recently commented on ZTS. Citigroup dropped their price target on Zoetis from $145.00 to $112.00 and set a "buy" rating on the stock in a report on Monday, May 18th. TD Cowen reduced their price objective on Zoetis from $150.00 to $104.00 and set a "buy" rating for the company in a research note on Tuesday, June 30th. HSBC decreased their target price on Zoetis from $140.00 to $95.00 and set a "buy" rating for the company in a research report on Monday, July 6th. Wall Street Zen downgraded shares of Zoetis from a "buy" rating to a "hold" rating in a report on Saturday, May 2nd. Finally, UBS Group reduced their price target on shares of Zoetis from $85.00 to $80.00 and set a "neutral" rating for the company in a research report on Friday. Seven research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $115.50.

Zoetis Company Profile

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source